| Patient | Flannery O'Connor |
|---|---|
| Date of birth | 2001-03-25 |
| Identifiers | MRN HR-ML046-SYN; SSN (made up) 000-46-1853 |
| Document date | 2026-04-29 |
| Author | Augusta Pemberton-Diallo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Kidney biopsy result and start of treatment. [S]
Ms. O'Connor had an ultrasound-guided kidney biopsy five days ago without bleeding. It shows ISN/RPS class III (A) lupus nephritis: focal endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, with no crescents or thrombotic microangiopathy. She heard the result from Dr. Okonjo-Strand by telephone two days ago, as she had asked, and again in full today. A levonorgestrel intrauterine system was inserted yesterday. Her joints and rash are unchanged; she has taken hydroxychloroquine and losartan for a week. Today she has the first of three methylprednisolone infusions, starts mycophenolate, and learns to give herself belimumab. She asked how to keep her mornings for writing through treatment. [S]
| Element | Detail |
|---|---|
| Biopsy | Class III (A) lupus nephritis; activity 6 of 24, chronicity 1 of 12 |
| Contraception | Intrauterine system inserted yesterday |
| Today | Methylprednisolone 500 mg (first of three); mycophenolate; first belimumab injection |
| Bone | DXA today |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue; low-grade fevers in the evenings |
| Musculoskeletal | Positive | Hand and knee pain and swelling unchanged; no hip or groin pain |
| Integumentary | Positive | Facial rash unchanged |
| Genitourinary | Negative | No pain at the biopsy site; no blood clots in the urine |
| Psychiatric | Negative | Determined; sleeping adequately |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2026-04-13 | active | S |
| Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Methylprednisolone 500 mg intravenous infusion once daily for three days | One infusion daily for three days | Intravenous route | 2026-04-29 to 2026-05-01 | completed | S |
| Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months | Once daily, tapering | Oral route | 2026-04-29 | active | S |
| Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily | Two tablets twice daily | Oral route | 2026-04-29 | active | S |
| Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly | Once weekly by self-injection | Subcutaneous route | 2026-04-29 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-04-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-29 | Body height | 168 | cm | S |
| 2026-04-29 | Body weight | 59.8 | kg | S |
| 2026-04-29 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 2026-04-29 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-04-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-04-29 | Heart rate | 84 | /min | S |
| 2026-04-29 | Respiratory rate | 14 | /min | S |
| 2026-04-29 | Body temperature | 37 | Cel | S |
| 2026-04-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-29 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-04-29 | Leukocytes [#/volume] in Blood by Automated count | 3.6 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-04-29 | Lymphocytes [#/volume] in Blood by Automated count | 0.9 | 10*3/uL | 1-4.8 10*3/uL | Low | S |
| 2026-04-29 | Platelets [#/volume] in Blood by Automated count | 151 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | <=33 U/L | Normal | S |
| 2026-04-29 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 26 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-04-29 | DXA Lumbar spine [Z-score] Bone density | -0.4 | {Z-score} | Z-score above -2.0 is within the expected range for age | Normal | S |
| 2026-04-29 | DXA Femur [Z-score] Bone density | -0.2 | {Z-score} | Z-score above -2.0 is within the expected range for age | Normal | S |
Vital signs recorded on 2026-04-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired, composed; temperature 37.0 °C |
| Back | Biopsy site clean and healing; no tenderness |
| Skin | Malar rash as before |
| Musculoskeletal | Synovitis of the hands and wrists as before; full painless hip movement |
| Cardiovascular | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be established | resolved | confirmed | M25.50 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D). |
| Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be established | resolved | confirmed | R80.9 | S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit. |
| Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negative | active | confirmed | M32.19 | S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used. |
| Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney function | active | confirmed | M32.14 | S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used. |
| Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or less | active | confirmed | Z79.52 | S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low. |
| Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in place | active | confirmed | Z79.624 | S — Synthetic treatment status. |
| Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatment | active | confirmed | Z97.5 | S — Synthetic contraception, chosen by the patient. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Kidney biopsy | Before treatment | Up to date | Class III (A); activity 6 of 24; chronicity 1 of 12 |
| Medication safety | Pulse methylprednisolone and oral taper plan | At the start of treatment | Completed today | 500 mg today and for two more days; written taper schedule given |
| Laboratory | Blood count and liver tests before mycophenolate | Before the first dose, then weekly for a month, twice monthly for two months, then monthly | Completed today | White cells 3.6, lymphocytes 0.9, hemoglobin 11.2, platelets 151; ALT 18 |
| Medication safety | Pregnancy test and contraception before mycophenolate | Before the first dose | Completed today | Pregnancy test negative; intrauterine system inserted yesterday |
| Medication safety | Belimumab start and injection teaching | At the start | Completed today | First 400 mg dose given under supervision; she injected herself; warned to report low mood |
| Imaging | Bone density (DXA) at the start of glucocorticoids | As soon as possible after starting | Completed today | Lumbar spine Z-score -0.4; femoral neck Z-score -0.2 |
| Laboratory | 25-hydroxyvitamin D | At the start of glucocorticoids | Completed today | 26 ng/mL; vitamin D3 started |
| Examination | Avascular necrosis symptoms | Every visit | Completed today | No hip, groin, or knee pain; full hip movement |
| Medication safety | Hydroxychloroquine baseline eye examination | Within the first year | Ordered | Ophthalmology booked in two months |
| Laboratory | Potassium and creatinine after starting losartan | 2 to 4 weeks after starting | Due | Losartan started a week ago; to be drawn with the blood counts in two weeks |
| Examination | Blood pressure | Every visit | Completed today | 128/80 mmHg on losartan |
| Laboratory | Urine protein-to-creatinine ratio, sediment, creatinine, anti-dsDNA, and complements | Every 3 months during active treatment | Due | At three months |
| Medication safety | Recombinant zoster vaccine dose 2 | 1 to 2 months after dose 1 | Due | At the three-month visit |
| Self-management | Writing life and treatment schedule | Every visit | Completed today | Infusions booked in the afternoons; injections at home |
Goal progress:
Guideline basis: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022); BENLYSTA (belimumab): prescribing information (subcutaneous dosing for lupus nephritis) (2026); CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026)
Follow-up: Methylprednisolone tomorrow and the day after. Rheumatology blood counts weekly. Ophthalmology in two months. Three-month review. Next scheduled visit 2026-07-27: three-month response assessment for lupus nephritis and glucocorticoid taper. [S]